Compsns. derived from i(mycobacterium vaccae) and methods for their use

A technology of mycobacterium vaccae, composition, applied in the field of treatment, immune disorders and cancer diseases, prevention and detection including infectious diseases, treatment of respiratory diseases and skin diseases, can solve side effects, can not eradicate virus , interference with infection performance, etc.

Inactive Publication Date: 2001-05-09
GENESIS RES & DEV
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, interferon treatment does not eradicate the virus, although it is helpful in interfering with some manifestations of the infection
Interferon therapy is also accompanied by systemic side effects, requires multiple injections into each individual wart, and has considerable economic costs (Kraus, S. J. et al., Review of Infectious Diseases 2 (6): S620-S632, 1990; Frazer, I. H., Current Opinion in Immunology 8(4): 484-491, 1996)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compsns. derived from i(mycobacterium vaccae) and methods for their use
  • Compsns. derived from i(mycobacterium vaccae) and methods for their use
  • Compsns. derived from i(mycobacterium vaccae) and methods for their use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Effects of Mice Immunized with Mycobacterium vaccae on Tuberculosis

[0134] This example illustrates the effect of immunizing mice with heat-killed M. vaccae or M. vaccae culture filtrates prior to challenge with live M. tuberculosis.

[0135] Mycobacterium vaccae (ATCC No. 15483) was cultured in sterile medium 90 (yeast extract, 2.5 g / l; tryptone, 5 g / l; glucose, 1 g / l) at 37°C. Cells were harvested by centrifugation, transferred to sterile Middlebrook 7H9 medium (DifcoLaboratoies, Detroit, MI, USA) containing glucose, and cultured at 37°C for 1 day. The medium was then centrifuged to pellet the bacteria and the culture filtrate was removed. The bacterial pellet was resuspended in phosphate-buffered saline at a concentration of 10 mg / ml, equal to 10 10 Mycobacterium vaccae / ml. The bacterial suspension was then autoclaved at 120°C for 15 minutes. The culture filtrate was collected through a 0.45 μm filter into sterile bottles.

[0136] As shown in Figure 1A, when ...

Embodiment 2

[0139] Immunization with M. vaccae intradermal and intrapulmonary routes

[0140] Effects on macaque tuberculosis

[0141] This example illustrates the effect of immunizing macaques by the intradermal and intrapulmonary routes with heat-killed M. vaccae or M. vaccae culture filtrates prior to challenge with live M. tuberculosis.

[0142]Heat-killed M. vaccae and M. vaccae culture filtrates were prepared as described in Example 1 above. Five groups of macaques were used, with 2 monkeys in each group. Two groups of monkeys were immunized with whole heat-killed M. vaccae either intradermally or intrapulmonarily; two groups of monkeys were immunized with M. vaccae culture filtrate either intradermally or intrapulmonarily; and the control group received no immunization. All immunogens will be dissolved in phosphate buffered saline. Table 1 provides the composition used to immunize each group of monkeys, the amount of immunogen and the route of administration. Before immunizatio...

Embodiment 3

[0156] Effects of Immunization with Mycobacterium vaccae on Asthma in Mice

[0157] This example demonstrates the ability to suppress allergic immune responses in the lungs when heat-killed M. vaccae and DD-M. vaccae were administered intranasally to mice. This was demonstrated in a mouse model of asthma-like allergen-specific lung disease. The severity of this allergic disease is reflected in the large number of eosinophils that accumulate in the lungs.

[0158] C57BL / 6J mice were given 2 μg ovalbumin in 100 μl alum adjuvant by intraperitoneal route at time 0 and 14 days, followed by 100 μg ovalbumin in 50 μl phosphate-buffered saline (PBS) by intranasal route on day 28 protein. It was detected by washing the airways of anesthetized mice with saline, collecting the washings (bronchoalveolar lavage, or BAL), and counting eosinophils, which the mice had accumulated in their lungs.

[0159] Such as Figure 2A and 2B As shown, compared with control mice, 10 or 1000 μg heat-ki...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides compositions which are present in or may be derived from Mycobacterium vaccae, together with methods for their use in the treatment, prevention and detection of disorders including infectious diseases, immune disorders and cancer. Methods for enhancing the immune response to an antigen including administration of M. vaccae culture filtrate, delipidated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells depleted of mycolic acids, and delipidated and deglycolipidated M.vaccae cells depleted of mycolic acids and arabinogalactan are also provided.

Description

technical field [0001] The present invention relates generally to compositions present in or obtainable from Mycobacterium vaccae and their use in the treatment, prevention and detection of diseases including infectious diseases, immune disorders and cancer. In particular, the present invention relates to compositions and methods for the treatment of respiratory diseases such as mycobacterial infections, asthma, sarcoidosis and lung cancer, and skin diseases such as psoriasis, Atopic dermatitis, allergic contact dermatitis, patchy alopecia, and skin cancers basal cell carcinoma, squamous cell carcinoma, and melanoma. The invention also relates to compounds useful as non-specific immune response enhancers, and the use of such non-specific immune response enhancers as adjuvants in vaccination or immunotherapy against infectious diseases and in the treatment of certain immune disorders and cancer. Background of the invention [0002] Tuberculosis is a chronic infectious diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/569A61K31/711A61K38/00A61K39/00A61K39/04A61K48/00A61P11/00A61P11/06A61P17/00A61P17/06A61P31/00A61P31/06A61P37/04C07K14/35C07K16/12C07K19/00C12N1/19C12N1/21C12N5/10C12N15/09C12N15/31C12P21/08C12Q1/02C12R1/32G01N33/68
CPCC07K2319/00A61K2039/51C07K14/35A61K48/00A61K38/00A61K39/04A61K39/00A61P11/00A61P11/06A61P17/00A61P17/06A61P31/00A61P31/06A61P37/04
Inventor P·坦J·瓦特森E·S·维赛尔M·A·斯金纳R·L·普雷斯蒂德格
Owner GENESIS RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap